Cargando…
P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429211/ http://dx.doi.org/10.1097/01.HS9.0000969864.18372.7f |
| _version_ | 1785090653878747136 |
|---|---|
| author | Krishnappa, Manjunath Mandavia, Divyesh Jain, Minish S, Mukesh Patel, Ankit Agarwal, Anshul Giri, Sanjeev Kumar Tiwari, Nirbhay Thiyagarajan, Saravanan Dey, Mamon Padmanabha Naidu, Gutta Ramachandra, Murali Kumar, Akhil |
| author_facet | Krishnappa, Manjunath Mandavia, Divyesh Jain, Minish S, Mukesh Patel, Ankit Agarwal, Anshul Giri, Sanjeev Kumar Tiwari, Nirbhay Thiyagarajan, Saravanan Dey, Mamon Padmanabha Naidu, Gutta Ramachandra, Murali Kumar, Akhil |
| author_sort | Krishnappa, Manjunath |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429211 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104292112023-08-17 P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES Krishnappa, Manjunath Mandavia, Divyesh Jain, Minish S, Mukesh Patel, Ankit Agarwal, Anshul Giri, Sanjeev Kumar Tiwari, Nirbhay Thiyagarajan, Saravanan Dey, Mamon Padmanabha Naidu, Gutta Ramachandra, Murali Kumar, Akhil Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429211/ http://dx.doi.org/10.1097/01.HS9.0000969864.18372.7f Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Krishnappa, Manjunath Mandavia, Divyesh Jain, Minish S, Mukesh Patel, Ankit Agarwal, Anshul Giri, Sanjeev Kumar Tiwari, Nirbhay Thiyagarajan, Saravanan Dey, Mamon Padmanabha Naidu, Gutta Ramachandra, Murali Kumar, Akhil P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES |
| title | P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES |
| title_full | P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES |
| title_fullStr | P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES |
| title_full_unstemmed | P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES |
| title_short | P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES |
| title_sort | p740: pk, pd and safety of first-in-human, first-in-class phase i trial (aur103-101; bharat) of aur103, an oral cd47 inhibitor, in patients with advanced malignancies |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429211/ http://dx.doi.org/10.1097/01.HS9.0000969864.18372.7f |
| work_keys_str_mv | AT krishnappamanjunath p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT mandaviadivyesh p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT jainminish p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT smukesh p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT patelankit p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT agarwalanshul p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT girisanjeev p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT kumartiwarinirbhay p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT thiyagarajansaravanan p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT deymamon p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT padmanabhanaidugutta p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT ramachandramurali p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies AT kumarakhil p740pkpdandsafetyoffirstinhumanfirstinclassphaseitrialaur103101bharatofaur103anoralcd47inhibitorinpatientswithadvancedmalignancies |